Centrally authorised Medicinal Products for Human and Veterinary Use

by | May 23, 2017 | Blog, Brexit, Good Distribution Practice - GDP, WDA(H)

The UK triggered Article 50 of the Treaty on European Union on 29th of March 2017 and as a result all primary and secondary law ceases to apply to the UK from 30th of March 2019.

Companies who hold centrally authorised “MA s” must proactively review their MA terms, submit any required variations and ensure that their processes and controlled documents are updated in plenty of time for the pending exit of The UK from the EU to ensure continuity of supply.

EU law requires that pharmacovigilance and batch release etc. must be performed in the EU or EEA and that MA holders are established in the EU or EEA.

The European Medicines Agency has a useful page on its website which contains helpful information.

Testimonials

“It is always difficult to provide and undertake virtual training. Wes did well getting through all the material and encouraged interaction among the group. This was difficult but at times good discussion did open up. There were no technical difficulties in terms of the training provision, and everything ran to time, if not a bit quicker than expected. I did enjoy it and remained engaged throughout. There was a lot of content and to begin with I felt a little overwhelmed and anxious about t… Read more
Cogent Gold Standard Responsible Person Training - Nov 2020